Dice Therapeutics

Dice Therapeutics is a biotechnology company located in South San Francisco, California, dedicated to creating innovative oral medicines for autoimmune and inflammatory diseases. The company’s lead program specifically targets the IL-17 cytokine, which is significant in the treatment of psoriasis and other IL-17 mediated diseases. Dice Therapeutics employs its proprietary DELSCAPE platform to identify and develop selective oral small molecules capable of modulating protein-protein interactions. Their development pipeline features several oral small molecule therapeutics aimed at IL-17, integrins, and PD-L1, addressing various diseases. Currently, Dice Therapeutics is conducting a Phase 1 trial for DC-853 and a Phase 2b trial for DC-806, both targeting psoriasis. The company is also focused on developing oral alternatives to treatments that are traditionally available only in injectable forms.